目的 觀察注射用益氣復(fù)脈（凍干）治療不穩(wěn)定型心絞痛的療效及安全性。方法 選取2022年1月—2023年1月延邊大學(xué)附屬醫(yī)院心內(nèi)科因不穩(wěn)定型心絞痛住院患者103例，根據(jù)治療方案不同分為對照組（n=53）及試驗(yàn)組（n=50）。對照組患者給予常規(guī)治療方案，包括一般治療（吸氧、低鹽低脂飲食、雙聯(lián)抗血小板治療、調(diào)脂＋穩(wěn)定斑塊治療、擴(kuò)血管治療）；試驗(yàn)組在與對照組相同的常規(guī)治療基礎(chǔ)上聯(lián)用注射用益氣復(fù)脈（凍干），每次取5.2 g加入0.9%氯化鈉注射液或5%葡萄糖注射液250 mL，靜脈滴注，每天1次，連續(xù)用藥7 d。觀察兩組患者心絞痛癥狀（周發(fā)作頻率、單次發(fā)作持續(xù)時間）、西雅圖心絞痛（SAQ）評分、超敏-C反應(yīng)蛋白（hs-CRP）及低密度脂蛋白-膽固醇（LDL-C）變化。觀察兩組治療期間不良反應(yīng)發(fā)生情況。結(jié)果 試驗(yàn)組在心絞痛癥狀（周發(fā)作頻率、單次發(fā)作持續(xù)時間）改善、SAQ評分改善方面均優(yōu)于對照組（P＜0.05）；試驗(yàn)組心電圖有效率（86.00%）高于對照組（64.15%，P＜0.05）；試驗(yàn)組治療總有效率（92.00%）也高于對照組（75.47%，P＜0.05）；治療后，兩組患者血清hs-CRP、LDL-C水平均較本組治療前顯著降低（P＜0.05）；相較于對照組，試驗(yàn)組治療后hs-CRP水平及LDL-C水平更加降低（P＜0.05）。兩組治療期間各有1例患者出現(xiàn)皮疹或頭暈，兩組總不良反應(yīng)發(fā)生率比較，差異無統(tǒng)計學(xué)意義（P＞0.05）。結(jié)論 注射用益氣復(fù)脈（凍干）可減少心絞痛周發(fā)作次數(shù)、縮短單次發(fā)作時間、改善SAQ評分，也有著更高的心電圖改善率及總有效率，療效顯著，安全性也較好。

Objective To observe the efficacy and safety of Yiqi Fumai Lyophilized Injection in treatment of unstable angina pectoris. Methods From January 2022 to January 2023, 103 inpatients with unstable angina pectoris in the Department of Cardiology of the Affiliated Hospital of Yanbian University were selected and divided into the control group (n=53) and the experimental group (n=50) according to the different treatment schemes. The patients in the control group were treated with traditional chemical drugs, including general treatment (oxygen inhalation, low salt low-fat diet, treatment of diabetes, hypertension and other complications, removal of incentives, etc.), dual antiplatelet therapy (aspirin+clopidogrel), lipid regulation+stable plaque therapy (atorvastatin or rosuvastatin), and vasodilator therapy. On the basis of the same routine treatment method as the control group, the experimental group was combined with Yiqi Fumai Lyophilized Injection. Each time, 5.2 g of Yiqi Fumai Lyophilized Injection was taken, and 250 mL of 0.9% Sodium Chloride Injection or 5% Glucose Injection was added for preparation. The drug was administered intravenously once a day for seven consecutive days. The changes in symptoms of angina pectoris (weekly frequency, duration of single episode), Seattle angina pectoris (SAQ) score, inflammation index hypersensitive C-reactive protein (hs-CRP), and blood lipid index low-density lipoprotein cholesterol (LDL-C) in two groups of patients were observed. The occurrence of adverse reactions during treatment in both groups were observed. Results The experimental group showed better improvement in angina symptoms (weekly frequency, duration of single episode) and SAQ scores compared to the control group (P＜0.05). The effective rate of electrocardiogram in the experimental group (86.0%) was higher than that in the control group (68.0%, P＜0.05). The overall effective rate of the experimental group (92.0%) was also higher than that of the control group (75.6%, P＜0.05). Compared to the control group, the experimental group showed even lower levels of hs-CRP and LDL-C after treatment (P＜0.05). During the treatment period, one patient in each group experienced rash or dizziness, and there was no statistically significant difference in the overall incidence of adverse reactions between the two groups (P＞0.05). Conclusion Yiqi Fumai Lyophilized Injection can reduce the number of weekly episodes of angina pectoris, shorten the time of single episode, improve SAQ score, and also have a higher electrocardiogram improvement rate and overall effective rate. The therapeutic effect is significant, and the safety is also good.

R972